Long-term safety and pharmacodynamics of mepolizumab in children with severe asthma with an eosinophilic phenotype
Author:
Funder
GlaxoSmithKline
Genentech
Publisher
Elsevier BV
Subject
Immunology,Immunology and Allergy
Reference32 articles.
1. Prevalence of severe childhood asthma according to the WHO;Nordlund;Respir Med,2014
2. Worldwide trends in the prevalence of asthma symptoms: phase III of the International Study of Asthma and Allergies in Childhood (ISAAC);Pearce;Thorax,2007
3. Incidence and risk factors of pediatric asthma exacerbations in a multinational, multidatabase cohort study;Baan;Eur Respir J,2018
4. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma;Chung;Eur Respir J,2014
5. Severe asthma in school-age children: evaluation and phenotypic advances;Coverstone;Curr Allergy Asthma Rep,2015
Cited by 66 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Mepolizumab in children and adolescents with severe eosinophilic asthma not eligible for omalizumab: a single Center experience;Journal of Asthma;2024-01-19
2. 抗IL-5抗体（メポリズマブ）;Nihon Shoni Arerugi Gakkaishi. The Japanese Journal of Pediatric Allergy and Clinical Immunology;2023-12-20
3. The Saudi initiative for asthma – 2024 update: Guidelines for the diagnosis and management of asthma in adults and children;Annals of Thoracic Medicine;2023-12-15
4. A real-world disproportionality analysis of mepolizumab based on the FDA adverse event reporting system;Frontiers in Pharmacology;2023-12-07
5. Efficacy and Safety of Mepolizumab in the Management of Severe Eosinophilic Asthma: A Systematic Review;Cureus;2023-12-01
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3